JP2022540333A5 - - Google Patents
Info
- Publication number
- JP2022540333A5 JP2022540333A5 JP2021576580A JP2021576580A JP2022540333A5 JP 2022540333 A5 JP2022540333 A5 JP 2022540333A5 JP 2021576580 A JP2021576580 A JP 2021576580A JP 2021576580 A JP2021576580 A JP 2021576580A JP 2022540333 A5 JP2022540333 A5 JP 2022540333A5
- Authority
- JP
- Japan
- Prior art keywords
- alkylene
- unsubstituted
- substituted
- cancer
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962872593P | 2019-07-10 | 2019-07-10 | |
| US62/872,593 | 2019-07-10 | ||
| PCT/US2020/041175 WO2021007307A1 (en) | 2019-07-10 | 2020-07-08 | Bcl-2 protein inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022540333A JP2022540333A (ja) | 2022-09-15 |
| JP2022540333A5 true JP2022540333A5 (enExample) | 2023-07-12 |
Family
ID=74114258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576580A Ceased JP2022540333A (ja) | 2019-07-10 | 2020-07-08 | Ｂｃｌ－２タンパク質阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220265834A1 (enExample) |
| EP (1) | EP3972966A4 (enExample) |
| JP (1) | JP2022540333A (enExample) |
| KR (1) | KR20220034805A (enExample) |
| CN (1) | CN114144411A (enExample) |
| AR (1) | AR119379A1 (enExample) |
| AU (1) | AU2020310147A1 (enExample) |
| CA (1) | CA3140085A1 (enExample) |
| IL (1) | IL289622A (enExample) |
| MX (1) | MX2022000310A (enExample) |
| TW (1) | TW202116758A (enExample) |
| WO (1) | WO2021007307A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023515050A (ja) * | 2020-02-21 | 2023-04-12 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | ジフルオロメチルヨード化合物及び方法 |
| CA3173843A1 (en) * | 2020-04-28 | 2021-11-04 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| JP2024505562A (ja) | 2021-02-02 | 2024-02-06 | レス ラボラトイレス セルビエル | 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法 |
| AU2023264537A1 (en) | 2022-05-06 | 2024-11-14 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| EP4519260A1 (en) | 2022-05-06 | 2025-03-12 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xdegraders |
| PE20250007A1 (es) | 2022-05-06 | 2025-01-07 | Treeline Biosciences Inc | Degradadores bcl-xl-heterobifuncionales de tetrahidroisoquinolina |
| KR20260111020A (ko) | 2023-11-07 | 2026-07-14 | 트리라인 바이오사이언시스, 인크. | 테트라히드로이소퀴놀린 이종이작용성 bcl-xl 분해제 |
| AU2024378690A1 (en) | 2023-11-07 | 2026-05-07 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders |
| IL327973A (en) | 2023-11-07 | 2026-06-01 | Treeline Biosciences Inc | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| CN118908940B (zh) * | 2024-10-11 | 2024-12-31 | 齐鲁理工学院 | 一种靶向抗凋亡Bcl-2的蛋白水解靶向嵌合体的制备和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| CN109152933B (zh) * | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| IL316472A (en) * | 2018-01-10 | 2024-12-01 | Recurium Ip Holdings Llc | Benzamide compounds |
| ES3041854T3 (en) * | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
| CA3173843A1 (en) * | 2020-04-28 | 2021-11-04 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
-
2020
- 2020-07-08 AU AU2020310147A patent/AU2020310147A1/en not_active Abandoned
- 2020-07-08 WO PCT/US2020/041175 patent/WO2021007307A1/en not_active Ceased
- 2020-07-08 AR ARP200101931A patent/AR119379A1/es not_active Application Discontinuation
- 2020-07-08 CN CN202080049518.8A patent/CN114144411A/zh active Pending
- 2020-07-08 CA CA3140085A patent/CA3140085A1/en active Pending
- 2020-07-08 US US17/597,474 patent/US20220265834A1/en not_active Abandoned
- 2020-07-08 EP EP20836203.8A patent/EP3972966A4/en not_active Withdrawn
- 2020-07-08 KR KR1020227002987A patent/KR20220034805A/ko not_active Withdrawn
- 2020-07-08 TW TW109123006A patent/TW202116758A/zh unknown
- 2020-07-08 JP JP2021576580A patent/JP2022540333A/ja not_active Ceased
- 2020-07-08 MX MX2022000310A patent/MX2022000310A/es unknown
-
2022
- 2022-01-04 IL IL289622A patent/IL289622A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7861083B2 (ja) | Ｆａｋ阻害剤およびその併用薬物 | |
| RU2020102453A (ru) | Фармацевтические композиции | |
| ES2760462T3 (es) | Tratamiento dirigido del leiomiosarcoma | |
| BRPI0721905B1 (pt) | composto inibidor de proteassoma, sua composição farmacêutica e seu uso | |
| JP7304128B2 (ja) | 白金耐性の克服における使用のためのテキサフィリン－白金（ｉｖ）コンジュゲート及び組成物 | |
| JP2009530392A5 (enExample) | ||
| JP2013538213A5 (enExample) | ||
| JP2019534865A5 (enExample) | ||
| WO2024212430A1 (zh) | 一种新型紫杉烷类化合物的制备方法、应用 | |
| CN108250250B (zh) | 含1,1,1-三苯基-n-(1-(吡啶-2-)亚甲基)甲胺的配合物及制备方法、应用 | |
| WO2023078426A1 (zh) | 一种化合物、包含其的药物组合物及其应用 | |
| JP2008508287A5 (enExample) | ||
| JP6104287B2 (ja) | 四環系アントラキノン誘導体 | |
| JP2016532714A5 (enExample) | ||
| JP2014510699A5 (enExample) | ||
| TW483897B (en) | New bis-platinum complexes with polyamine ligands as antitumor agents | |
| ES2947326T3 (es) | Procedimiento de producción de un derivado de imidazo[1,2-b]piridazina 3,6-disubstituido | |
| JP2005501121A5 (enExample) | ||
| Zhang et al. | Synthesis and biological evaluation of novel dinuclear platinum (II) complexes derived from a novel chiral ligand | |
| JP2010500971A5 (enExample) | ||
| CN110393714B (zh) | 一种抗肿瘤药物、合成方法及应用 | |
| CN103145762B (zh) | 含有芳基位阻基团的二价铂配合物、制备方法及其应用 | |
| CN102898449B (zh) | 一种合成克里唑替尼中间体的方法 | |
| CN107129465B (zh) | 芳基胍类化合物及其制备方法和用途 | |
| CN102070615B (zh) | 氮氧自由基抗肿瘤药物 |